Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=felip
“The information presented here showed that for patients included in the ASCEND 3 trial—ALK positive patients previously treated with chemotherapy—who received ceritinib as their first ALK inhibitor there [was] an overall survival of 51 months. This is really encouraging,” said lead author Enriqueta Felip MD PhD, medical oncologist and Chair of the Thoracic Malignancies Group at Vall d’Hebron University Hospital in Barcelona, Spain, talking to the Audio Journal of Oncology.
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=felip
“The information presented here showed that for patients included in the ASCEND 3 trial—ALK positive patients previously treated with chemotherapy—who received ceritinib as their first ALK inhibitor there [was] an overall survival of 51 months. This is really encouraging,” said lead author Enriqueta Felip MD PhD, medical oncologist and Chair of the Thoracic Malignancies Group at Vall d’Hebron University Hospital in Barcelona, Spain, talking to the Audio Journal of Oncology.
The podcast Audio Journal of Oncology Podcast is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.